kein plan von der firma, habe dieses gefunden. kurs war schon bei
ueber $31 am 12/03/01, jetzt $25.
Bei Biotechs halte ich mich an Biogen,Amgen,Genzyme zunaechst fest.
Kleine Kaeufe von AVGN, oder wie Du MLNM sind okay, leider fehlt der
earnings report und MLNM erwartet einen netten loss per share for
first quarter, 0.12 per share estimated, was weitaus hoeher liegt als
4. quartal 2000, naemlich 0.02 cents per share.
ABBOTT PARK, Ill., March 12 (Reuters) - Health-care company Abbott Laboratories Inc.
has agreed to purchase $250 million in shares of Millennium Pharmaceuticals Inc. , with which it has formed an alliance to discover, develop and commercialize drugs for obesity and diabetes, the companies said on Monday.
As part of the five-year agreement, Abbott will buy $50 million in Millennium stock at closing and $200 million over the next two years, the companies said.
Both companies said they will contribute their metabolic disease research pipelines exclusively to the new partnership, with more than 35 projects in the alliance at the outset.
Abbott and Millennium also expect to deliver two drug candidates into the clinic by 2002 and two to three drug candidates per year thereafter, Jeffrey Leiden, Abbott executive vice president, pharmaceuticals, and chief scientific officer, said in a statement.
"Abbott's goal for this alliance is to strengthen our position in the metabolic disease field through the expansion of our current corporate-wide franchises in diabetes and obesity, which include diagnostics, nutritionals and newly acquired BASF pharmaceutical products," Chairman and Chief Executive Miles White said in the statement.
Both companies said they will share costs related to the development of drug candidates already in their metabolic disease pipelines. The program will be staffed by 225 scientists, with expansion planned over the term of the agreement. The companies said they will share profits worldwide.
Millennium, a leading biopharmaceutical company based in Cambridge, Mass., has developed a genomics technology platform to identify genes linked to obesity and diabetes. It holds a number of key patents relating to satiety, fat absorption and energy metabolism.
Abbott, a global diversified health-care company, develops, manufactures and markets pharmaceutical, diagnostic, nutritional and hospital products.
Werbung
